Gao Yaning, Chen Liang, Wen Zhengjun, Jiang Huiying, Feng Jing
Respiratory and Critical Care Medicine Department, Beijing Jingmei Group General Hospital, Beijing, People's Republic of China.
Infect Drug Resist. 2024 Nov 3;17:4833-4841. doi: 10.2147/IDR.S479374. eCollection 2024.
PURPOSE: Our aim was to determine the risk factors for multidrug resistance in patients with carbapenem-resistant (CRKP). METHODS: The information of 196 patients with infection was collected. The patients were subsequently assigned to the carbapenem-resistant, multidrug-resistant, and non-multidrug-resistant groups. The risk factors for multidrug resistance in CRKP patients were assessed via least absolute shrinkage and selection operator and logistic regression analyses. Moreover, a nomogram was constructed dependent on the identified risk factors, and calibration and decision curves were plotted to detect its accuracy. RESULTS: Length of stay (LOS) [odds ratio (OR) and 95% confidence interval (CI): 4.558 (1.157-17.961), P = 0.030], intensive care unit (ICU) stay within 30 days [OR and 95% CI: 12.643 (3.780-42.293), P < 0.001], Glasgow Coma Scale (GCS) score [OR and 95% CI: 13.569 (2.738-67.236), P = 0.001], fungal infection [OR and 95% CI: 6.398 (1.969-20.785), P = 0.002], and cardiovascular disease (CVD) [OR and 95% CI: 3.871 (1.293-11.592), P = 0.016] were identified as risk factors for multidrug resistance in CRKP patients. The concordance index (C-index) of the constructed nomogram was 0.950 (95% CI: 0.945-0.955). Moreover, decision curve analysis elucidated the nomogram utilization across a wide range of probability thresholds, ranging from 1% to 100%. Finally, internal validation using random data validated the robustness of the predictive model, yielding a C-index of 0.937. CONCLUSION: The LOS, ICU stay within 30 days, GCS score, fungal infection, and CVD were recognized as risk factors for multidrug resistance in CRKP patients. The constructed nomogram could accurately predict multidrug-resistant CRKP infections in patients.
Infect Drug Resist. 2024-11-3
Infect Drug Resist. 2022-5-3
Front Cell Infect Microbiol. 2021
Front Microbiol. 2025-1-23
Heliyon. 2024-3-18
Trends Immunol. 2023-10
Indian J Med Res. 2023-6
Clin Interv Aging. 2023
Front Cell Infect Microbiol. 2023
Antibiotics (Basel). 2023-1-21
Front Public Health. 2022